FDA approves first PI3K inhibitor for breast cancer

13:11 EDT 24 May 2019 | FDA Voice

FDA approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant.

Original Article: FDA approves first PI3K inhibitor for breast cancer

More From BioPortfolio on "FDA approves first PI3K inhibitor for breast cancer"